• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Portfolia Invests in Xandar Kardian for Health Monitoring

by Fred Pennic 02/27/2023 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Portfolia Invests in Xandar Kardian for Health Monitoring

What You Should Know:

– Portfolia, the world’s most powerful community of women investors, has officially announced a significant investment in Xandar Kardian from the firm’s Active Aging I and Active Aging II funds. Portfolia’s investment represents a core contribution to Xandar Kardian’s $10 million Series A Funding round.

– Portfolia sees Xandar Kardian’s impact extends well beyond the traditional hospital room, with impressive potential growth opportunities into a wider breadth of long-term care subcategories in the coming years – including assisted living, independent living and active adult living communities.

Digital Automation with Radar Accuracy

Founded in 2017 as a US Delaware C-Corp with international operations spanning South Korea, Canada and the United States, Xandar Kardian is led by CEO and founder Sam Yang with a mission of deploying reliable and high-accuracy cleantech, smart building and healthcare solutions worldwide. Xandar Kardian’s XK300 became the first continuous, autonomous radar-powered health monitoring system to achieve FDA 510(k) clearance as a Class II Medical Device for non-invasive monitoring. The product’s sensors provide critical early deterioration detection in healthcare settings by measuring 6000+ RHR (Resting Heart Rate) & RR (Respiratory Rate) readings a day, as opposed to a traditional hospital setting, where these vital signs are measured manually only 4 to 6 times a day.

The Xandar Kardian XK300 Autonomous Health Monitoring Solution achieved 510(k) Clearance by the U.S. Food & Drug Administration in April 2021, paving the way for a new era of accurate and reliable healthcare technology. With 23 patents granted and 11 pending, Xandar Kardian’s technology has received more than 25 accolades and awards over the last few years – among them being inclusion on TIME’s Best Inventions of 2022, Fast Company’s Most Innovative Companies of 2022, and 11 CES Innovation Awards.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: FDA, healthcare technology, Heart, Medical Device, Patents, sensors, Vital

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |